ORIGINAL ARTICLE

Gene expression networks in COPD: microRNA and mRNA regulation

Michael E Ezzi,¹ Melissa Crawford,¹ Ji-Hoon Cho,² Robert Orellana,¹ Shile Zhang,² Richard Gelinas,² Kara Batte,¹ Lianbo Yu,¹ Gerard Nuovo,¹ David Galas,² Philip Diaz,¹ Kai Wang,² S Patrick Nana-Sinkam¹

► Additional data are published online only. To view these files please visit the journal online (<http://thorax.bmj.com/content/67/2.toc>).

¹Department of Medicine, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Medical Center, Columbus, Ohio, USA

²Institute for Systems Biology, Seattle, Washington, USA

Correspondence to

Dr S Patrick Nana-Sinkam, Ohio State University Medical Center, Davis HLRI, 473 W 12th Ave, Room 201, Columbus, OH 43210, USA; patrick.nana-sinkam@osumc.edu

ME and MC contributed equally to this manuscript.

Received 24 February 2011

Accepted 21 August 2011

Published Online First

22 September 2011

ABSTRACT

Background The mechanisms underlying chronic obstructive pulmonary disease (COPD) remain unclear. MicroRNAs (miRNAs or *miRs*) are small non-coding RNA molecules that modulate the levels of specific genes and proteins. Identifying expression patterns of miRNAs in COPD may enhance our understanding of the mechanisms of disease. A study was undertaken to determine if miRNAs are differentially expressed in the lungs of smokers with and without COPD. miRNA and mRNA expression were compared to enrich for biological networks relevant to the pathogenesis of COPD.

Methods Lung tissue from smokers with no evidence of obstructive lung disease (n=9) and smokers with COPD (n=26) was examined for miRNA and mRNA expression followed by validation. We then examined both miRNA and mRNA expression to enrich for relevant biological pathways.

Results 70 miRNAs and 2667 mRNAs were differentially expressed between lung tissue from subjects with COPD and smokers without COPD. miRNA and mRNA expression profiles enriched for biological pathways that may be relevant to the pathogenesis of COPD including the transforming growth factor β , Wnt and focal adhesion pathways. miR-223 and miR-1274a were the most affected miRNAs in subjects with COPD compared with smokers without obstruction. miR-15b was increased in COPD samples compared with smokers without obstruction and localised to both areas of emphysema and fibrosis. miR-15b was differentially expressed within GOLD classes of COPD. Expression of SMAD7, which was validated as a target for miR-15b, was decreased in bronchial epithelial cells in COPD.

Conclusions miRNA and mRNA are differentially expressed in individuals with COPD compared with smokers without obstruction. Investigating these relationships may further our understanding of the mechanisms of disease.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a worldwide epidemic primarily attributable to the effects of cigarette smoke. It is a heterogeneous disease defined by airflow limitation that is not fully reversible and an abnormal inflammatory response of the lung to noxious stimuli.¹ Mechanisms implicated include those directly attributable to the effects of cigarette smoke such as cellular injury, inflammation and abnormal repair.²

Key messages

What is the key question?

- Chronic obstructive pulmonary disease (COPD) is a worldwide health crisis mostly attributable to cigarette smoking.
- The precise mechanisms underlying COPD development are not clear, but genomic and proteomic studies are improving our understanding of the pathogenesis of this disease.
- Researchers have identified abnormal expression of microRNAs (miRNAs or *miRs*) in several types of cancers, but our knowledge of the significance of these small molecules in diseases other than cancer including COPD is just emerging.

What is the bottom line and why read on?

- 70 miRNAs that were differentially expressed in lung tissue from smokers without COPD and those with COPD (GOLD stages 1, 2 and 4) were identified.
- The correlation between differentially expressed miRNAs and genes suggests potentially functional relationships that may contribute to the pathogenesis of COPD.

MicroRNAs (miRNAs, *miR*) are one member of a family of small non-coding RNAs (approximately 21–25 nucleotides long) encoded in the genome of organisms ranging from animals and plants to viruses.³ These molecules represent components of the human genome that were previously thought to be non-functional. miRNAs are integral to key biological functions and modulate both gene and protein levels by either destabilising transcripts or inhibiting protein translation. Given the relative redundancy of complementary sequences between miRNAs and their target mRNA, single miRNAs have the capacity to regulate tens to hundreds of genes simultaneously. In fact, it is estimated that miRNAs may target up to one-third of the transcriptome.⁴

miRNA deregulation has been implicated in the pathogenesis of several diseases including both haematological and solid malignancies. miRNA expression patterns in primary tumour tissues, blood, sputum and urine are being investigated as biomarkers for both diagnosis and prognosis in disease. These miRNA signatures may eventually be applied to clinical practice. Our knowledge of the role of miRNAs in the pathogenesis of lung

Table 1 Demographic characteristics of study patients

	Normal smokers (N=9)	GOLD 1 (N=7)	GOLD 2 (N=9)	GOLD 4 (N=10)	p Value
Men (%)	44	42.8	44	60	0.880
Age	63.22±11.43	69.71±7.39	69.11±7.30	50.90±5.62	<0.0001
Pack-years of smoking	25.67±16.70	41.86±23.26	44.00±20.15	56.40±36.42	0.106
SGRQ score	11.86±17.27	31.90±19.35	36.79±16.79	61.05±15.62	<0.0001
BMI	28.76±6.81	26.97±4.10	26.50±5.23	24.88±2.59	0.409
FEV ₁ PD	104.22±15.50	89.00±5.77	70.56±5.05	21.20±7.96	<0.0001

BMI, body mass index; FEV₁ PD, forced expiratory volume in 1 s percentage predicted; NA, not available; SGRQ, St George Respiratory Questionnaire score.

disease is rapidly expanding, and miRNAs appear to be important in maintaining homeostasis during lung development and may have a pathogenic role in lung disease.^{5–6} In addition, miRNAs may be involved in the regulation of inflammation in the lung in response to exogenous stimuli in animal models.^{7–8}

Little is known regarding the role of miRNAs in COPD. Two studies have investigated the effects of cigarette smoke on miRNA expression.^{9–10} In the first study 24 miRNAs were significantly downregulated between smoke-exposed rats and sham groups.⁹ In the second study the effects of smoke exposure on miRNA expression in mice were investigated.¹⁰ The majority of deregulated miRNAs in this study were also downregulated.

Similar studies are being conducted in specific cell types in smokers and subjects with COPD. Schembri *et al* compared miRNA and mRNA expression in airway epithelial cells from smokers versus never smokers.¹¹ Twenty-eight miRNAs were differentially expressed, with the majority downregulated in smokers. Sato *et al* examined the expression of *miR-146a* in fibroblasts from subjects with and without COPD.¹² *miR-146a* expression in cultured fibroblasts was reported to correlate with COPD severity as assessed by expiratory airflow.

Our goal in this study was to determine if miRNAs were differentially expressed in the lungs of patients with COPD and if miRNA expression may be linked to mRNA expression and thus biological pathways relevant to the pathogenesis of COPD. We compared miRNA and mRNA expression patterns in lung tissue from subjects with different Global Initiative for Obstructive Lung Disease (GOLD) stages of COPD and smokers without airflow limitation. We enriched for predicted miRNA targets in our group of deregulated mRNAs. Lastly, we identified transforming growth factor (TGF)- β , Wnt and focal adhesion pathways as potential pathways in which miRNAs may be relevant to the pathogenesis of COPD.

METHODS

Additional details of methods are shown in the online supplement.

Subject selection

Thirty-five tissue samples were procured through a Lung Tissue Research Consortium approved project (#07-99-0008) for the purposes of miRNA and mRNA analysis. Clinical information available for the subjects included age, gender, height, weight and smoking history. Test results including spirometry, pathological diagnosis and the results of the St George Respiratory Questionnaire health surveys were available.

Tissue processing and RNA isolation

Total RNA was isolated from frozen tissue samples using a freeze fracture protocol, followed by Trizol extraction and precipitation at -20°C overnight to increase the yield of small RNAs. RNA integrity was determined by capillary electrophoresis on an Agilent 2100 Bioanalyzer. Only RNA with an integrity number ≥ 7 was used in the profiling studies.

miRNA microarray

miRNAs were profiled in subjects with COPD (N=19) and normal smokers (N=8) using Exiqon miRNA microarrays according to the manufacturer's instructions (Exiqon, Woburn, Massachusetts, USA). The labelled miRNA probes were hybridised to the miRCURY LNA arrays v.11.0 for 16 h at 56°C . After hybridisation the arrays were washed and scanned at $5\mu\text{m}$ resolution using a ScanArray Express (Perkin Elmer, Waltham, Massachusetts, USA).

Messenger RNA microarray

Samples were prepared for mRNA microarray analysis using Agilent Quick Amp Labeling technologies (Santa Clara, California, USA). Hybridised slides were then washed and scanned with ScanArray Express (Perkin Elmer).

mRNA and miRNA microarray data processing

For mRNA data, raw intensities from all samples were merged, normalised using the quantile method and transformed into $\log_2$ scale.¹³ Present probes with mean intensity over all samples larger than the global mean intensity were chosen and used for

Figure 1 Hierarchical clustering result of differentially expressed microRNAs (miRNAs) in lungs from subjects with chronic obstructive pulmonary disease (COPD) compared to smokers without COPD. Exiqon miRCURY LNA microRNA Array v11 was used for miRNA expression profiling. Seventy differentially expressed miRNAs (DEmiRNAs) were identified between COPD samples (n=19) and smokers without obstruction (n=8) which showed a positive false discovery rate <0.05 and fold changes $\geq \pm 1.5$ using the LIMMA method.

Table 2 Top 10 upregulated microRNAs in lungs from subjects with COPD compared with smokers without COPD

	Fold difference (COPD/normal smokers)	p Value	pFDR value
hsa-miR-223	2.93	6.63E-04	1.37E-03
hsa-miR-1274a	2.73	3.19E-10	4.44E-09
hsa-miR-144	2.38	2.83E-03	4.26E-03
hsa-miR-374a	2.25	1.72E-04	4.74E-04
hsa-miR-664	2.21	2.00E-08	2.02E-07
hsa-miR-148a	2.15	2.34E-07	1.68E-06
hsa-miR-766	2.06	1.05E-05	4.76E-05
hsa-miR-486-5p	2.05	3.26E-04	8.21E-04
hsa-miR-10a	2.05	7.47E-04	1.46E-03
hsa-miR-451	2.00	5.39E-02	4.59E-02

COPD, chronic obstructive pulmonary disease; pFDR, positive false discovery rate.

further statistical analysis. LIMMA¹⁴ and QVALUE¹⁵ R packages were used to perform statistical testing of differential mRNA and miRNA expression between control smoker and COPD samples and to compute the positive false discovery rate (pFDR), respectively. Present probes were used for statistical testing to increase the ratio of true positives to false positives,¹⁶ and differentially expressed mRNAs and miRNAs were defined as having a pFDR <0.05 with at least ± 1.5 -fold change between the groups.

Quantitative reverse transcription PCR validation

Independent assays were performed using quantitative reverse transcription PCR (qRT-PCR) on all patient samples for individual miRNA (*miR-15b*, *miR-223*, *miR-1274a* and *miR-424*) and mRNA (telomerase associated protein 1 (TEP1), interleukin 6 (IL-6), catalase (CAT) and mothers against decapentaplegic homologue 7 (Drosophila) (SMAD7) (Applied Biosystems, Foster City, California, USA). All RT-PCR experiments were performed in three independent experiments conducted in triplicate on all study samples. Data were presented relative to either 18s for mRNA or U43 for miRNA based on calculations of $2^{(-\Delta Ct)}$. Statistical significance was defined as $p < 0.05$ as measured by the

Table 3 Top 10 downregulated microRNAs in lungs from subjects with COPD compared with smokers without COPD

miRNA	Fold difference (COPD/normal smokers)	p Value	pFDR value
hsa-miR-923	-5.06	5.88E-06	2.91E-05
hsa-miR-937	-2.36	1.89E-06	1.08E-05
hsa-miR-422a	-2.12	1.45E-06	8.74E-06
hsa-miR-576-3p	-2.06	1.57E-06	9.22E-06
hsa-miR-513a-5p	-2.06	3.57E-04	8.54E-04
hsa-miR-25*	-2.01	2.10E-07	1.56E-06
hsa-miR-99b*	-1.81	1.23E-05	5.25E-05
hsa-miR-125b-1*	-1.75	1.38E-05	5.70E-05
hsa-miR-24	-1.75	1.59E-04	4.49E-04
hsa-miR-187*	-1.64	3.14E-04	8.04E-04

*indicates miRNA on the opposite arm of the hairpin during processing.
COPD, chronic obstructive pulmonary disease; pFDR, positive false discovery rate.

Student t test or ANOVA (see tables E1 and E2 in online supplement for sequences of miRNA and mRNA probes).

Functional enrichment study

In order to identify Kyoto Encyclopedia of Genes and Genomes (KEGG)¹⁷ pathways associated with a set of genes, we used DAVID¹⁸ and obtained the list of enriched pathways. Their p values were computed by a modified Fisher exact test called the EASE score method.¹⁸

Target prediction and network analysis

Predicted target genes for miRNAs were obtained using TargetScan v5.1, PicTar and miRanda. For differentially expressed miRNAs, all predicted targets in human genes and predicted targets overlapping with differentially expressed genes were used to perform KEGG pathway enrichment analysis. To describe the potential relationship between differentially expressed genes and miRNAs in a KEGG pathway, the predicted miRNA gene pairs from TargetScan showing negative expression correlations (< -0.5) were incorporated into the pathway diagram. A modified KEGG pathway diagram was generated using Cytoscape.¹⁹

Figure 2 Quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation of differentially expressed microRNAs (miRNAs). qRT-PCR was performed on the same RNA samples (nine normal smokers and 26 subjects with chronic obstructive pulmonary disease) by individual miRNA for (A) *miR-15b*, (B) *miR-223*, (C) *miR-1274a* and (D) *miR-424*. All RT-PCR experiments were performed in two independent experiments conducted in triplicate. Data are presented as $2^{(-\Delta Ct)}$ relative to U43. There was a statistically significant difference as measured by the Student t test in subjects with chronic obstructive pulmonary disease (COPD) compared with normal smokers for *miR-15b*, *miR-223*, *miR-1274a* and *miR-424*.

Figure 3 Hierarchical clustering result of differentially expressed genes in subjects with chronic obstructive pulmonary disease (COPD) compared with smokers without COPD. There were 2667 differentially expressed genes between subjects with COPD (N=23) and smokers without COPD (N=9). Hierarchical clustering result showed the clear separation of COPD patient samples from smokers without COPD samples. Normal: smokers without airflow limitation.

In situ hybridisation and co-localisation

Co-localisation analyses of SMAD7, cytokeratin AE 1/3 and *miR-15b* expression were conducted as previously described.²⁰ After development the slide was analysed with the Nuance system (Cambridge Research and Instrumentation, Hopkinton, MA). The Nuance system converts the blue and brown signals to fluorescent blue and red, respectively, then mixes them to determine if a given cell contains both targets. The negative

controls were the omission of the probe and the use of a scrambled probe, as previously described.²⁰

Transfection studies and western blot analyses

Details of transfection studies and western blot analyses are shown in the online supplement.

TGF β treatment

Beas2B cells were transfected with either scrambled or pre-miR15b as described above. 72 h after transfection the cells were starved for 6 h followed by treatment with TGF β (5 ng/ml; Sigma, St Louis, Missouri, USA). The cells were harvested at 10, 15 and 30 min and assessed for phosphorylated SMAD 3 protein expression (Cell Signaling, Danvers, Massachusetts, USA).

Migration assay

The migration rate was assayed using the IBIDI culture insert (München, Germany). Images were taken on an Olympus IX81 immediately (time 0) and again at 8 and 24 h. Seven random widths were measured across the wound at time 0. The number of pixels was converted to microns and the line was then superimposed onto the subsequent time points. The mean and SD of the seven lines was calculated using ImageJ software to determine the distance of wound closure. Experiments were performed in triplicate.

RESULTS

Study subjects

Tissue samples were obtained from subjects with GOLD stages 1, 2 and 4 COPD (N=26) and from smokers without evidence of obstruction (N=9) from the Lung Tissue Research Consortium. There were no pathological or clinical diagnoses of cancer across the COPD or control tissue specimens. GOLD stage 4 tissue was obtained from explanted lungs. Tissue from smokers without airflow obstruction and GOLD stages 1 and 2 tissue was obtained mainly by wedge resection with pathology showing no evidence of cancer. Demographic information is presented in table 1 with accompanying summary statistics for each group.

There was an overall difference between the mean ages of all subjects ($p<0.0001$). Subjects with GOLD stage 4 COPD were younger than those with GOLD 1 COPD ($p<0.001$), GOLD 2 COPD ($p<0.001$) and smokers without airflow limitation

Table 4 Top 10 upregulated mRNA in lung tissue from subjects with COPD compared with smokers without COPD

Gene ID	Gene title	Gene symbol	Fold difference (COPD/normal smokers)	p Value	pFDR value	Function
9507	ADAM metallopeptidase with thrombospondin type 1 motif, 4	ADAMTS4	8.91	2.16E-04	4.02E-04	Proteolytic activity
7011	Telomerase-associated protein 1	TEP1	7.24	4.88E-13	5.06E-11	Alternative splicing, nucleo-cytoplasmic transport
10949	Heterogeneous nuclear ribonucleoprotein A0	HNRNPA0	6.86	8.02E-22	5.24E-18	mRNA processing, transport and metabolism
2304	Forkhead box E1 (thyroid transcription factor 2)	FOXE1	6.30	4.02E-05	1.01E-04	Transcription factor, thyroid gland organogenesis
4001	Lamin B1	LMNB1	6.05	8.44E-12	4.52E-10	Nuclear stability, chromatin structure
117245	HRAS-like suppressor family, member 5	HRASLS5	5.26	1.59E-17	1.44E-14	Transferase, catalytic activity
3569	Interleukin 6 (interferon, beta 2)	IL6	5.18	1.50E-03	2.01E-03	Inflammation, B cell differentiation
6280	S100 calcium binding protein A9	S100A9	5.14	8.17E-07	4.14E-06	Cell cycle progression, differentiation, immune system
6696	Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T lymphocyte activation 1)	SPP1	5.10	6.58E-05	1.51E-04	Metabolic process, cellular organisation, binding
27097	TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65 kDa	TAF5L	4.95	2.05E-12	1.51E-10	Histone acetylase

COPD, chronic obstructive pulmonary disease; pFDR, positive false discovery rate.

Table 5 Top 10 downregulated mRNA in lung tissue from subjects with COPD compared with smokers without COPD

Gene ID	Gene title	Gene symbol	Fold difference (COPD/normal smokers)	p Value	pFDR value	Function
22870	SAPS domain family, member 1	SAPS1	−4.46	3.15E-03	3.69E-03	Protein phosphatase
6435	Surfactant, pulmonary-associated protein A1B	SFTPA1B	−4.23	2.90E-08	2.76E-07	Binds surfactant phospholipids
5507	Protein phosphatase 1, regulatory (inhibitor) subunit 3C	PPP1R3C	−4.17	3.99E-05	1.01E-04	Glycogen-targeting subunit, increases glycogen
2662	Growth differentiation factor 10	GDF10	−4.14	3.07E-05	8.04E-05	TGFβ signalling
5350	Phospholamban	PLN	−3.93	1.78E-06	7.72E-06	Calcium regulation
25928	Sclerostin domain containing 1	SOSTDC1	−3.87	2.68E-04	4.79E-04	Inhibits TGFβ signalling and enhances Wnt signalling
9353	Slit homologue 2 (Drosophila)	SLIT2	−3.48	4.32E-08	3.81E-07	Cell migration and axonal navigation
4094	v-maf musculoaponeurotic fibrosarcoma oncogene homologue (avian)	MAF	−3.46	1.41E-06	6.35E-06	Transcriptional activator or repressor, oncogene or tumor suppressor depending on context
123624	ATP/GTP binding protein-like 1	AGBL1	−3.37	7.95E-06	2.66E-05	Tubulin processing
4629	Myosin, heavy chain 11, smooth muscle	MYH11	−3.31	2.09E-06	8.78E-06	Contractile protein

COPD, chronic obstructive pulmonary disease; pFDR, positive false discovery rate; TGFβ, transforming growth factor β.

($p=0.013$) (see table E6 in online supplement). There was no overall difference in pack years between the groups ($p=0.106$). Subjects with GOLD stage 4 tended to have more smoke exposure than smokers without airflow limitation ($p=0.068$; see table E7 in online supplement). The overall difference in scores on the St George Respiratory Questionnaire and forced expiratory volume in 1 s percentage predicted were significant ($p<0.0001$) as expected (see table E8 in online supplement).

MicroRNAs are differentially expressed between COPD and control lung tissues

Seventy miRNAs were differentially expressed between COPD tissue ($N=19$) and tissue from smokers without airflow limitation ($N=8$), as shown in figure 1. Thirteen miRNAs were downregulated in COPD tissue and 57 were upregulated. *miR-223* and *miR-1274a* were increased in expression by nearly threefold in COPD samples compared with smokers without

airflow limitation (table 2). *miR-923* had an average decrease in expression of fivefold in COPD tissue compared with tissue from smokers without airflow limitation (table 3).

QT-PCR validation of differentially expressed microRNAs between COPD and control lung tissues

We validated miRNAs (*miR-15b*, *miR-223*, *miR-1274a* and *miR-424*) by qRT-PCR, as shown in figure 2. *miR-223* and *miR-1274a* were chosen for further validation based on dramatic increases in expression in COPD samples. *miR-15b* and *miR-424* were chosen for validation based on target prediction results and the potential role of these miRNAs in enriched pathways including TGF-β. The expression of *miR-223*, *miR-1274a*, *miR-15b* and *miR-424* was verified by quantitative PCR between all COPD samples ($n=26$) and all tissue samples from smokers without airflow limitation ($n=9$) and found to be of statistical significance (figure 2).

Figure 4 Quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation of differentially expressed mRNAs. qRT-PCR was performed on the same RNA samples by mRNA TaqMan assay for (A) interleukin 6 (IL-6); (B) telomerase associated protein 1 (TEP1); (C) catalase (CAT) and (D) mothers against decapentaplegic homologue 7 (Drosophila) (SMAD7). All RT-PCR experiments were performed in three independent experiments conducted in triplicate. Data are presented as $2^{(-\Delta Ct)}$ relative to 18s RNA. In cases in which $p<0.0001$, values are presented as $p=0.0001$.

Figure 6 In situ hybridisation for mature *miR-15b*. Correlation of *miR-15b* and mothers against decapentaplegic homologue 7 (*Drosophila*) (*SMAD7*) expression with lung histopathology. (A) Lack of expression of scrambled miRNA as a control. (B) Normal lung where the *miR-15b* signal is intense in the epithelial cells of larger bronchi (arrowhead) (each image at 200 $\times$). (C) Same area at higher magnification (400 $\times$) where a nuclear and cytoplasmic signal is evident. (D) *miR-15b* signal in alveoli in a patient with emphysema and increased lung fibrosis (400 $\times$). (E) *miR-15b* in epithelial cells at the junction of areas of emphysema and fibrosis (arrowheads) (50 $\times$). (F) Same region showing no *SMAD7* (50 $\times$). (G) *SMAD7* in normal regions of bronchial epithelium (red stain) (100 $\times$). (H) Distribution of *SMAD7* protein in a normal larger bronchus in a section of lung (200 $\times$). The nuclear-based signal involves primarily bronchial epithelial cells and mononuclear cells in the adjacent lymphoid infiltrate.

SMAD3 in response to $TGF\beta$ treatment. (figure 8C). *miR-15b* knockdown had the opposite effect with reduced early phosphorylation of *SMAD3* (figure 8C) Lastly, we examined the effects of *miR-15b* on Beas2B proliferative and migratory capacity, both of which are altered by $TGF\beta$. Cells transfected with *miR-15b* demonstrated increased migration (figure 8D) and attenuated proliferative capacity (not shown).

DISCUSSION

We conducted a comprehensive analysis of miRNA and mRNA expression in whole lung samples from subjects with COPD compared with smokers without COPD and identified 70 differentially expressed miRNAs in COPD tissue compared with tissue from smokers without airflow limitation. *miR-223* and *miR-1274a* were the most differentially expressed miRNAs with a near threefold increase in expression in COPD samples. *miR-1274a* has yet to be well described, and recent studies suggest that it harbours significant homology with the transfer RNA Lysine 5 (tRNA^{Lys5}).³¹ tRNAs are primarily responsible for amino acid transfer.³¹ Two recent studies demonstrated upregulation of *miR-223* in murine lungs following exposure to

aerosolised lipopolysaccharide and downregulation following exposure to cigarette smoke.^{7,9}

We compared our list of differentially expressed miRNAs with those previously reported in smokers by Schembri *et al.*¹¹ The miRNAs that were differentially expressed in our study as well as the previous report included *miR-223*, *miR-18a*, *miR-106a*, *miR-146*, *miR-99a*, *miR-150* and *miR-365*. Of these differentially expressed miRNAs, however, *miR-18a* and *miR-365* were the only ones that were increased in expression in both datasets. While the previous study examined airway epithelial cells, we examined whole lung tissue in this study. This may account for the differences in expression patterns. In our study we found increased expression of *miR-146a* in subjects with COPD compared with smokers without obstruction. The previous study by Sato and colleagues reported reduced expression of *miR-146a* in cultured fibroblasts from COPD subjects.¹² Again, this was a cell-specific finding as opposed to our whole lung expression analysis. Lastly, Van Pottelberge *et al* recently identified differences in miRNA expression (including decreased *Let-7c*) in induced sputum from smokers and individuals with COPD.³² The authors determined that predicted target genes for *Let-7c* were enriched for in sputum from patients with COPD.

Figure 7 Co-expression of *miR-15b* and mothers against decapentaplegic homologue 7 (*Drosophila*) (*SMAD7*) in the lung. This is a representative section of the lung of a subject with chronic obstructive pulmonary disease and associated increased pulmonary fibrosis. All panels are at 200 $\times$. (A) Regular colour image after co-expression of *miR-15b* (blue) and *SMAD7* (brown). The images were analysed by the Nuance system which converted the *miR-15b* image to fluorescent blue (B) and the *SMAD7* image to fluorescent red (C, note the stromal dominance). (D) Mixed image where the absence of fluorescent yellow indicates that the cells expressing *miR-15b* are mutually exclusive from those expressing *SMAD7*. As a positive control, (E) represents co-expression of *miR-15b* (blue) and AE 1/3 (brown) in the bronchial epithelium. (F) Co-localisation is evident by the intense yellow signal.

Several genes that are part of the TGF β superfamily were differentially expressed in our data. We identified downregulation of BMP5 and BMP6, TGF β R1 and TGF β R2 and SMAD7. SMAD7 was of particular interest given that it is downregulated in bronchial biopsies of patients with COPD and serves as an inhibitory SMAD in TGF β signalling.³³ We validated SMAD7 expression in COPD lung tissue by qRT-PCR and by protein in a subset of patients (see figure E4 in online supplement).

miR-15b, 424 and 107, which were all increased in COPD lung tissue, are members of the *miR15/107* family.³⁴ Termed the AGC2 miRNAs because of their common 5' end (AGCAGC), this group of miRNAs has been implicated in several processes including cell division, stress, angiogenesis and cancer.³⁴ Lung tissue from patients with GOLD stage 4 COPD had the highest expression of *miR-15b* compared with subjects with other GOLD stages and normal smokers (see figure E1 in online supplement). We demonstrated that overexpression of *miR-15b* in a bronchial epithelial cell line reduced SMAD7, SMURF2 and downstream decorin protein. Conversely, knockdown of *miR-15b* resulted in increased SMAD7, decorin and SMURF2 proteins. Functionally, *miR-15b* manipulation altered early SMAD3 phosphorylation in response to TGF β treatment.

Wnt (Wingless and Int-1) signalling has been implicated in normal epithelial and mesenchymal function during lung development and dysregulation observed in lung cancer, pulmonary fibrosis and pulmonary hypertension.³⁵ Dysregulation of several Wnt pathway-related genes in COPD has recently been reported in COPD.³⁰ Expression of Wnt receptors frizzled homologue (FZD) 5 and FZD 7 were downregulated by 1.76-fold and 1.57-fold, respectively, in our data. With the integration of mRNA and miRNA profiling, we identified several miRNAs that may target the main hubs of this network (see figure E2 in online supplement).

In this study we have presented both mRNA and miRNAs in COPD lung tissue compared with smokers without obstruction. We recognise the limitations of this study, including the lack of phenotypic information of importance such as body composition, frequency of exacerbations, hypoxaemia, perception of dyspnoea or systemic involvement of disease. Our samples were defined by GOLD stages based on spirometric values. There is an inherent limitation in defining patients with COPD by these criteria alone since different phenotypes of disease exist in COPD. We were able to evaluate the available clinical information on these subjects, but factors such as oxygen use, inhaled

steroid use and time since the last cigarette use were not available in the dataset. In addition, we recognise the lack of reproducibility between high throughput studies of the transcriptome and proteome over the past decade.^{36–38} These differences may be due to tissue heterogeneity and differences in platforms. However, overall, a few common gene ontology terms are consistently deregulated including cellular organisation and biogenesis, response to stress, organ development, cell adhesion and cellular metabolic process.^{36–38}

We propose several miRNAs—including members of the *miR* 15/107 family—that deserve further investigation in the regulation of *TGFβ* signalling in COPD. Expressed miRNAs and mRNAs viewed as networks should generate hypotheses about the key pathologies of inflammation and tissue destruction in this and other diseases of the lung.

Acknowledgements We thank the Lung Tissue Research Consortium (LTRC) for collecting and providing subject specimens.

Funding This work was supported by NIH grant R03 HL095425 (SNS) and by the Flight Attendant Medical Research Institute (FAMRI) (MEE), Pulmonary Systems Biology Initiative of the Battelle Memorial Institute (KW, SZ, RG) as well as support from the University of Luxembourg and the Luxembourg Centre for Systems Biomedicine (DG, KW, JHC, RG).

Competing interests None.

Ethics approval This study was approved by IRB Ohio State University.

Contributors ME, SPN, MC, KW, RG, JC, PD and DG were responsible for preparation of the manuscript; MC, RO and KB conducted in vitro experiments; GN conducted all immunohistochemistry and in situ studies; KW, JC and LY conducted all network and statistical array analysis.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All data generated will be uploaded to the appropriate online genomic data banks.

REFERENCES

1. Fabbri LM, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of COPD: 2003. *Eur Respir J* 2003;**22**:1–2.
2. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur Respir J* 2003;**22**:672–88.
3. Ambros V. The functions of animal microRNAs. *Nature* 2004;**431**:350–5.
4. Lim LP, Lau NC, Garrett-Engle P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* 2005;**433**:769–73.
5. Nana-Sinkam SP, Hunter MG, Nuovo GJ, et al. Integrating the MicroRNome into the study of lung disease. *Am J Respir Crit Care Med* 2009;**179**:4–10.
6. Nana-Sinkam SP, Karsies T, Riscili B, et al. Lung MicroRNA: from development to disease. *Expert Rev Respir Med* 2009;**3**:373–85.
7. Moschos SA, Williams AE, Perry MM, et al. Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. *BMC Genomics* 2007;**8**:240.

8. **Zhai Y**, Zhong Z, Chen CY, *et al*. Coordinated changes in mRNA turnover, translation, and RNA processing bodies in bronchial epithelial cells following inflammatory stimulation. *Mol Cell Biol* 2008;**28**:7414–26.
9. **Izzotti A**, Calin GA, Arrigo P, *et al*. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. *FASEB J* 2009;**23**:806–12.
10. **Izzotti A**, Calin GA, Steele VE, *et al*. Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. *FASEB J* 2009;**23**:3243–50.
11. **Schembri F**, Sridhar S, Perdomo C, *et al*. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. *Proc Natl Acad Sci U S A* 2009;**106**:2319–24.
12. **Sato T**, Liu X, Nelson A, *et al*. Reduced MiR-146a increases prostaglandin E2 in chronic obstructive pulmonary disease fibroblasts. *Am J Respir Crit Care Med* 2010;**182**:1020–9.
13. **Bolstad BM**, Irizarry RA, Astrand M, *et al*. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics* 2003;**19**:185–93.
14. **Smyth GK**. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol* 2004;**3**:Article3.
15. **Storey JD**, Tibshirani R. Statistical significance for genomewide studies. *Proc Natl Acad Sci U S A* 2003;**100**:9440–5.
16. **McClintick JN**, Edenberg HJ. Effects of filtering by Present call on analysis of microarray experiments. *BMC Bioinformatics* 2006;**7**:49.
17. **Kanehisa M**, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000;**28**:27–30.
18. **Huang da W**, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009;**4**:44–57.
19. **Shannon P**, Markiel A, Ozier O, *et al*. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003;**13**:2498–504.
20. **Nuovo GJ**, Elton TS, Nana-Sinkam P, *et al*. A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. *Nat Protoc* 2009;**4**:107–15.
21. **Zandvoort A**, Postma DS, Jonker MR, *et al*. Altered expression of the Smad signalling pathway: implications for COPD pathogenesis. *Eur Respir J* 2006;**28**:533–41.
22. **He JQ**, Foreman MG, Shumansky K, *et al*. Associations of IL6 polymorphisms with lung function decline and COPD. *Thorax* 2009;**64**:698–704.
23. **Kuhn C 3rd**, Homer RJ, Zhu Z, *et al*. Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. *Am J Respir Cell Mol Biol* 2000;**22**:289–95.
24. **Tomaki M**, Sugiura H, Koarai A, *et al*. Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD lung. *Pulm Pharmacol Ther* 2007;**20**:596–605.
25. **Churg A**, Wang R, Wang X, *et al*. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. *Thorax* 2007;**62**:706–13.
26. **Churg A**, Dai J, Tai H, *et al*. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. *Am J Respir Crit Care Med* 2002;**166**:849–54.
27. **He JQ**, Shumansky K, Connett JE, *et al*. Association of genetic variations in the CSF2 and CSF3 genes with lung function in smoking-induced COPD. *Eur Respir J* 2008;**32**:25–34.
28. **Wang IM**, Stepaniants S, Boie Y, *et al*. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. *Am J Respir Crit Care Med* 2008;**177**:402–11.
29. **Barnes PJ**. The cytokine network in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2009;**41**:631–8.
30. **Kneidinger N**, Yildirim AO, Callegari J, *et al*. Activation of the WNT/beta-catenin pathway attenuates experimental emphysema. *Am J Respir Crit Care Med* 2011;**183**:723–33.
31. **Schopman NC**, Heynen S, Haasnoot J, *et al*. A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. *RNA Biol* 2010;**7**:573–6.
32. **Pottelberge GR**, Mestdagh P, Bracke KR, *et al*. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2011;**183**:898–906.
33. **Springer J**, Scholz FR, Peiser C, *et al*. SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitory SMAD 6 and 7 by cigarette smoke. *Biol Chem* 2004;**385**:649–53.
34. **Finnerty JR**, Wang WX, Hebert SS, *et al*. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. *J Mol Biol* 2010;**402**:491–509.
35. **Konigshoff M**, Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal? *Am J Respir Cell Mol Biol* 2010;**42**:21–31.
36. **Golpon HA**, Coldren CD, Zamora MR, *et al*. Emphysema lung tissue gene expression profiling. *Am J Respir Cell Mol Biol* 2004;**31**:595–600.
37. **Ning W**, Li CJ, Kaminski N, *et al*. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. *Proc Natl Acad Sci U S A* 2004;**101**:14895–900.
38. **Spira A**, Beane J, Pinto-Plata V, *et al*. Gene expression profiling of human lung tissue from smokers with severe emphysema. *Am J Respir Cell Mol Biol* 2004;**31**:601–10.

British Thoracic Society

BTS SHORT COURSE

Practical update on the Management of Pulmonary Embolism

Course fees held at 2011 prices for BTS members

A new practical and interactive BTS Short Course based on real-life medicine and tackling key questions on Pulmonary Embolism.

24 April 2012, Hatton Garden, London

Limited places so early booking is advised.

For more information and to book your place on a BTS Short Course in 2012, visit:
www.brit-thoracic.org.uk

Working for healthier lungs